Who makes Amonafide and Cytarabine?

Amonafide and Cytarabine is developed by Antisoma Research.

What development phase is Amonafide and Cytarabine in?

Amonafide and Cytarabine is in Phase 3.

Last reviewed 2026-04-20 · How we verify

Amonafide and Cytarabine

Antisoma Research · Phase 3 active Small molecule Quality 0/100

At a glance

Generic name	Amonafide and Cytarabine
Sponsor	Antisoma Research
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML) (PHASE2)
Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study (PHASE3)
Amonafide in Combination With Cytarabine in Secondary AML (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Amonafide and Cytarabine CI brief — competitive landscape report
Amonafide and Cytarabine updates RSS · CI watch RSS
Antisoma Research portfolio CI